These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20948315)

  • 1. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.
    Ertel A; Dean JL; Rui H; Liu C; Witkiewicz AK; Knudsen KE; Knudsen ES
    Cell Cycle; 2010 Oct; 9(20):4153-63. PubMed ID: 20948315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.
    Witkiewicz AK; Ertel A; McFalls J; Valsecchi ME; Schwartz G; Knudsen ES
    Clin Cancer Res; 2012 Sep; 18(18):5110-22. PubMed ID: 22811582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.
    Martin KJ; Patrick DR; Bissell MJ; Fournier MV
    PLoS One; 2008 Aug; 3(8):e2994. PubMed ID: 18714348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen.
    Lehn S; Fernö M; Jirström K; Rydén L; Landberg G
    Cell Cycle; 2011 Mar; 10(6):956-62. PubMed ID: 21358261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
    Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
    Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
    J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
    Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
    Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
    West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
    Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
    [No Abstract]   [Full Text] [Related]  

  • 12. Pan-cancer molecular analysis of the RB tumor suppressor pathway.
    Knudsen ES; Nambiar R; Rosario SR; Smiraglia DJ; Goodrich DW; Witkiewicz AK
    Commun Biol; 2020 Apr; 3(1):158. PubMed ID: 32242058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
    Yau C; Benz CC
    Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in projecting clustering results across gene expression-profiling datasets.
    Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer.
    Arima Y; Hayashi N; Hayashi H; Sasaki M; Kai K; Sugihara E; Abe E; Yoshida A; Mikami S; Nakamura S; Saya H
    Int J Cancer; 2012 Jun; 130(11):2568-79. PubMed ID: 21717460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based gene signature is predictive of breast cancer survival and chemoresponse.
    Rathnagiriswaran S; Wan YW; Abraham J; Castranova V; Qian Y; Guo NL
    Int J Oncol; 2010 Mar; 36(3):607-16. PubMed ID: 20126981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.
    Musgrove EA; Sutherland RL
    Cell Cycle; 2010 Dec; 9(23):4607. PubMed ID: 21260944
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.